Sulfonylurea-induced hypoglycemia. An iatrogenic and potentially deadly complication;Sulfonylureaindusert hypoglykemi. En iatrogen og potensielt dodelig tilstand

Tidsskrift for den Norske Laegeforening

Volumn 117, Issue 21, 1997, Pages 3079-3082

  Carlsen, Sven M ^a  

^a Endokrinologisk Seksjon   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; SULFONYLUREA DERIVATIVE;

AGED; ARTICLE; CLINICAL ARTICLE; DEATH; HUMAN; HYPOGLYCEMIA; IATROGENIC DISEASE; MALE;

AGED; GLYBURIDE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; IATROGENIC DISEASE; MALE; SULFONYLUREA COMPOUNDS;

EID: 0030826762     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Karttunen P, Uusitupa M, Nykänen S, Robinson JD, Sipilä J. The pharmacokinetics of glibenclamide: a single dose comparison of four preparations in human volunteers. Int J Clin Pharmacol Ther Toxicol 1985; 23: 642-6.
2. Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989; 321: 1231-45.
3. Rydberg T, Jönsson A, Røder M, Melander A. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care 1994; 17: 1026-30.
4. Hellman B, Sehlin J, Täljedal I-B. Glibenclamide is exceptional among hypoglycemic sulphonylureas in accumulating progressively in β-cell-rich pancreatic islets. Acta Endocr 1984; 105: 385-90.
5. Kobayashi KA, Bauer LA, Horn JR, Opheim K, Wood F, Kradjan WA. Glipizide pharmacokinetics in young and elderly volunteers. Clin Pharm 1988; 7: 224-8.
6. Wahlin-Boll E, Aimer LO, Melander A. Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabetics. Clin Pharmacokinet 1982; 7: 363-72.
7. Crookes MJ, Brown KF. Interaction of glipizide with human serum albumin. Biochem Pharmacol 1975; 24: 298-9.
8. Ozanne SE, Guest PC, Hutton JC, Hales CN. Intracellular localization and molecular heterogenity of the sulphonylurea receptor in insulin-secreting cells. Diabetologia 1995; 38: 277-82.
9. Groop L, Groop P-H, Stenman S, Saloranta C, Tötterman K-J, Fyhrquist F et al. Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment. Diabetes Care 1987; 10: 671-7.
10. Rosenstock J, Corrao PJ, Goldberg RB, Kilo C. Diabetes control in the elderly: a randomized, comparative study of glyburide versus glipizide in non-insulin-dependent diabetes mellitus. Clin Ther 1993; 15: 1031-40.
11. Schmitt JK. Clinical comparison of glipizide and glyburide. Diabetes Care 1989; 12: 39.
12. Birkeland KI, Mowinckel P, Furuseth K, Vaaler S, Melander A. Long-term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide. Diabetes Care 1994; 17: 45-9.
13. Brodows RG. Benefits and risks with glyburide and glipizide in elderly NIDDM patients. Diabetes Care 1992; 15: 75-80.
14. Alexis G, Henault R, Sparr HB. Conversion from glipizide to glyburide: long-term follow-up of a cost-impact survey focusing on the elderly. Clin Ther 1993; 15: 607-15.
15. Kilo C, Meenan A, Bloomgarten Z. Glyburide versus glipizide in the treatment of patients with non-insulin-dependent diabetes mellitus. Clin Ther 1992; 14: 801-12.
16. Fredriksen PK, Mogensen EF. A clinical comparison between glipizide (Glibenese) and glibenklamide (Daonil) in the treatment of maturity onset diabetes: a controlled double-blind cross-over study. Curr Ther Res 1982; 32: 1-7.
17. McIntyre HD, Ma A, Bird DM, Paterson CA, Cameron DP. Chronic sulfonylurea therapy augments basal and meal-stimulated insulin secretion while attenuating insulin responses to sulfonylurea per se. Diabetes Care 1992; 15: 1534-40.
18. Stenman S, Melander A, Groop P-H, Groop LC. What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 1993; 118: 169-72.
19. Wåhlin-Boll E, Sartor G, Melander A, Schersten B. Impaired effect of sulfonylurea following increased dosage. Eur J Clin Pharmacol 1982; 22: 21-5.
20. Gregorio F, Ambrosi F, Cristallini S, Pedetti M, Filliponi P, Santeusanio F. Therapeutical consideration of tolbutamide, glibenclamide, gliclazide, and gliquidone, at different glucose levels: in vitro effects on pancreatic A and B-cell function. Diabetes Res Clin Pract 1992; 18: 197-206.
21. Jenning AM, Wilson RM, Ward JD. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care 1989; 12: 203-8.
22. Berger W. Incidence of severe side-effects during therapy with sulfonylureas and biguanides. Horm Metabo Res 1985; 15 (suppl): 111-5.
23. Campbell IW. Metformin and the sulfonylureas. The comparative risk. Horm Metab Res 1985; 15 (suppl): 105-11.
24. Campbell IW. Hypoglycemia and type 2 diabetes: sulphonylureas. I: Frier BM, Fischer BM, red. Hypoglycemia and diabetes. London: Edward Arnold, 1993: 387-92.
25. Asplund K, Wiholm B-E, Lithner F. Glibenklamide-associated hypoglycemia: a report on 57 cases. Diabetologia 1983; 24: 412-7.
26. Edwards TH, Braunstein GD, Davidson MB. Glyburide-induced hypoglycemia in an elderly patient: similarity of first-generation and second-generation sulfonylurea agents. Mt Sinai J Med 1985; 52: 644-6.
27. Sonnenblick M, Shilo S. Glibenclimide induced prolonged hypoglycemia. Age Ageing 1986; 15: 185-9.
28. Harrower ADB. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. J Diabetes Complications 1994; 8: 201-3.
29. United Kingdom Prospective Diabetes Study Group. United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diet, sulfonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310: 83-8.
30. Berger W, Caduff F, Pasquel M, Rump A. Die relative Häufigkeit der schweren Sulfonylharnstoff-Hypoglykämie in den letzten 25 Jahren in der Schweiz. Schweiz Med Wochenschr 1986; 116: 145-51.
31. Hildebrant J. Therapie des Erwachsenendiabetes mit einem Sulfonylharnstoff der zweiten Generation - Gemeinschaftsstudie an 4667 Patienten. Therapiwoche 1982; 32: 2820-8.
32. Asplund K, Wiholm B-E, Lundman B. Severe hypoglycemia during treatment with glipizide. Diabet Med 1991; 8: 726-31.
33. Seltzer HS. Drug-induced hypoglycemia. Endocrinol Metab Clin North Am 1989; 18: 163-83.
34. Masbernard A, Giudicelli C, Massey J. Clinical experience with glipizide in the treatment of mostly complicated diabetes. Diabetologia 1973; 9 (suppl): 356-63.
35. Hartling SG, Faber OK, Wegmann M-L, Wåhlin-Boll E, Melander A. Interaction of ethanol and glipizide in humans. Diabetes Care 1987; 10: 683-6.
36. Fagan M. Hypoglykemisk hemiparese. Tidsskr Nor Lægeforen 1989; 109: 2773-4.